BrightGene Bio-Medical Technology Co. Ltd. Class A 688166
SSE · China · Health Technology
CNY 35.81+1.45 (+4.22%)
Market closed· · CNY · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market closed· · CNY · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
As competition in the weight loss drug market progressively intensifies, the latest Phase III clinical data disclosed by BrightGene Bio-Medical (688166.SH) for BGM0504 has reignited market attention.
Recently, BrightGene Bio-Medical Technology Co., Ltd. (hereinafter referred to as "BrightGene Bio-Medical " or "the Company") announced that its proprietary GLP-1 (glucagon-like peptide-1)/GIP (glucose-dependent insulinotropic polypeptide) dual receptor agonist, BGM0504 injection, has achieved positive topline results from a Phase III clinical trial (CTR20243983/NCT06704581) evaluating its efficacy and safety in participants with overweight or obesity.
BrightGene Bio-Medical Technology Co., Ltd. (hereinafter referred to as " BrightGene Bio-Medical" or "the Company") announced that its proprietary GLP-1 (glucagon-like peptide-1)/GIP (glucose-dependent insulinotropic polypeptide) dual receptor agonist, BGM0504 injection, has achieved positive topline results from a Phase III clinical trial (Study No.: BGM0504-III-WL) evaluating its efficacy and safety in participants with overweight or obesity. The study successfully met its primary endpoint and
As global markets grapple with AI-related concerns and fluctuating economic indicators, investors are increasingly scrutinizing stock valuations and the potential returns on technological investments. Amidst this backdrop, growth companies with high insider ownership can offer a unique appeal; such alignment between management and shareholder interests often suggests confidence in the company's long-term prospects.
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.